Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.

Authors :: Hulin C
Offner F
Moreau P
Roussel M
Belhadj K
Benboubker L
Caillot D
Facon T
Garderet L
Kuhnowski F
Stoppa AM
Kolb B
Tiab M
Jie KS
Westerman M
Lambert J
Pei L
Vanquickelberghe V
De Boer C
Vermeulen J
Kampfenkel T
Sonneveld P
Van de Donk NWCJ
Source :: Haematologica [Haematologica] 2021 Aug 01; Vol. 106 (8), pp. 2257-2260. Date of Electronic Publication: 2021 Aug 01.
Publication Year :: 2021

Subjects :: Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bortezomib therapeutic use
Dexamethasone therapeutic use
Humans
Stem Cell Transplantation
Stem Cells
Transplantation, Autologous
Multiple Myeloma diagnosis
Multiple Myeloma drug therapy
Thalidomide therapeutic use

Full Text Access

Tools